Our findings are in accordance with reported rates of CPM in P/LP BRCA1/2 variant carriers ranging between 0% and 49.3% while BC history, an aggregation of familial BC cases and a young age at cancer onset were predictive factors for bilateral risk‐reducing ME or CPM.40, 41, 42, 43. This evidence concerns the gene BRCA1 and breast cancer.